OPSYNVI® logo

This site is intended for
U.S. healthcare professionals

I Am a Patient or Caregiver
I Am a Healthcare Professional
OPSYNVI® logo

Enrollment and Prescription Form Available Soon

The Enrollment and Prescription Form is not yet available.

Please check back to download the latest form.

Return to home
Return to previous page
REDUCTION IN PVR

OPSYNVI® Provided Greater Reductions in PVR Compared With Macitentan and Tadalafil Alone1

Change in PVR at Week 16
(OPSYNVI® vs macitentan)1

OPSYNVI® clinical trial PVR results for OPSYNVI® versus MacitentanOPSYNVI® clinical trial PVR results for OPSYNVI® versus Macitentan

Change in PVR at Week 16
(OPSYNVI® vs tadalafil)1

OPSYNVI® clinical trial PVR results for OPSYNVI® versus TadalafilOPSYNVI® clinical trial PVR results for OPSYNVI® versus Tadalafil

Treatment with OPSYNVI® (macitentan/tadalafil) resulted in a statistically significant treatment effect in PVR vs macitentan monotherapy and tadalafil monotherapy1

Safety and TolerabilityYellow arrow
Request a Medical
Science Liaison (MSL)Contact your MSL Dark blue arrow

CL=confidence limits; PAH=pulmonary arterial hypertension; PVR=pulmonary vascular resistance.

Reference: 1. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc.

Johnson & Johnson logo

To report suspected adverse reactions, contact Johnson & Johnson at 1-800-526-7736,
or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Contact Medical Information >

THIS SITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.
© Actelion Pharmaceuticals US, Inc. 2024 09/24 cp-429496v2

Cookie Policy
No footer links content fetched